Important information

The information contained in this website is intended strictly for sophisticated institutions.

The information contained in this website, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure  that  the  information  contained  in  this  website is  accurate,  no  responsibility  can  be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this website (or any part of it) with the consent of Capital International Management Company Sàrl (“CIMC”), 37A avenue J.F. Kennedy, L-1855 Luxembourg.

The information contained in this website is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public.

The information contained in this website, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts  or  estimates  of  income.  These  forward-looking  statements  are  based  upon  certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this website, you should consult an authorised financial adviser.

ESG The future of health care: Medtech’s innovation hotspots

Belinda Gan Lily Ghebrai

16 December 2025

Chronic disease is on the rise and populations are ageing.

Innovative medical technology (medtech) that helps address some of the resulting challenges to health and well-being offers significant growth potential.

KEY TAKEAWAYS

  • Chronic diseases are among the leading causes of death worldwide, and their rising prevalence is driving massive spending in health care. Breakthroughs in medical technology are creating compelling long-term investment opportunities.
  • Diabetes is one of the chronic diseases on the rise. Medical devices to help monitor and manage the disease represent sizeable growth potential.
  • Radiology and cardiovascular devices are at the forefront of AI adoption, and cancer detection is poised for a technological revolution.
  • Novel consumer-facing medtech products, such as next-generation hearing aids, are a fast-changing area where we see new entrants driving disruption.

Taking the pulse on investment opportunities in medtech

Explore some of our investment team’s latest thinking on the products, and the health care and consumer firms to watch.

DOWNLOAD RESEARCH

Explore the latest research and insights in our environmental, social and governance (ESG) perspectives library

Explore now

Belinda Gan is an ESG investment director with 20 years of industry experience (as of 12/31/2024). She holds a bachelor's degree in commerce and a bachelor's degree in business systems from Monash University, Australia. She also holds the Chartered Financial Analyst® designation.

Lily Ghebrai is an ESG analyst at Capital Group covering biopharma, health care services and medtech. She has 10 years of investment industry experience and has been with Capital Group for one year (as of 12/31/2024). She holds a master's degree in public administration from The School of International and Public Affairs at Columbia University and a bachelor's degree from Middlebury College.

Your gateway to all things ESG at Capital Group

LEARN MORE
Past results are not predictive of results in future periods. It is not possible to invest directly in an index, which is unmanaged. The value of investments and income from them can go down as well as up and you may lose some or all of your initial investment. This information is not intended to provide investment, tax or other advice, or to be a solicitation to buy or sell any securities.
 
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. All information is as at the date indicated unless otherwise stated. Some information may have been obtained from third parties, and as such the reliability of that information is not guaranteed.
 
Capital Group manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organisation; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.